Specificity and nanomolar potency of melatonin on G-protein coupled melatonin MT<sub>1</sub> and MT<sub>2</sub> receptors expressed in HEK-293T human embryo kidney cells

Rafael Rivas-Santisteban<sup>1,2</sup>, Irene Reyes-Resina<sup>1,2,✉</sup>, Iu Raïch<sup>1</sup>, Jesús Pintor<sup>3</sup>, Hanan A. Alkozi<sup>3</sup>, Gemma Navarro<sup>2,4,✉</sup>, Rafael Franco<sup>1,2,✉</sup>

<sup>1</sup>Dept. Biochemistry and Molecular Biomedicine. School of Biology. Universitat de Barcelona. Barcelona. Spain.
<sup>2</sup>Centro de Investigación en Red, enfermedades Neurodegenerativas. CiberNed. Instituto de Salud Carlos III. Madrid. Spain.
<sup>3</sup>Optics School. Complutense University. Madrid. Spain.
<sup>4</sup>Dept. Biochemistry and Physiology. School of Pharmacy and Food Sciences. Universitat de Barcelona. Barcelona. Spain.

† In memoriam
▲Equal contribution
& Current address: RG Neuroplasticity, Leibniz Institute for Neurobiology. Magdeburg, Germany

* Correspondence: rfranco123@gmail.com; rfranco@ub.edu; Tel +34934021208

Pre-registered study. Hypotheses and action plans were registered at osf.io. Date: May 2019

Running title: The potency of melatonin on MT<sub>1</sub> and MT<sub>2</sub> receptors

Received: October 6, 2019; Accepted: December 11, 2019

ABSTRACT

This is a pre-registered study, i.e. a study whose hypotheses and experiments designed to address these hypotheses have been deposited in a database before starting the experiments. The study aims at assessing the G<sub>s</sub> versus G<sub>i</sub> coupling and the potency of melatonin in the human version of melatonin MT<sub>1</sub> and MT<sub>2</sub> G-protein-coupled receptors expressed in HEK-293T cells. The results show that these receptors are G<sub>i</sub> but not G<sub>s</sub> coupled. By using a standard procedure of modulation of 0.5 µM forskolin-induced cAMP levels, it was found that the potency on MT<sub>2</sub> receptor-mediated actions is in the low nanomolar range, but the potency on MT<sub>1</sub> receptor is in the high nanomolar range. The potency of melatonin to stimulate the MT<sub>2</sub> receptor is similar to that of a selective agonist, N-[2-(2-methoxy-6H-isoindolo[2,1-a]indol-11-yl)ethyl]butanamide (IIK7). Overall, the data on the potency of melatonin on its receptors will provide a new look for melatonin research. It is important to consider this finding for appropriately addressing physiological or therapeutic effects based on melatonin potency. Thus, the low doses of melatonin used in the existing prolonged release preparations or in other supplements should be revisited.

Key words: Melatonin receptor, melatonin, sleep, cAMP, signal transduction, binding, pharmacokinetics.
1. INTRODUCTION

Aiming at finding substances to treat vitiligo, a skin disease characterized by the occurrence of depigmentation areas, Lerner and Case reported, in 1959, that a substance produced by the mammalian pineal gland, caused the aggregation of melanin near the nucleus of the amphibian melanocytes (1). Later, they identified the active molecule, named it (melatonin) and further deciphered its chemical structure: N-acetyl-5-methoxytryptamine (2). Since then many functions of melatonin have been discovered. At present, melatonin is very popular and is recommended as a supplement for a variety of uses, the most common being sleep regulation (3-9); it is even available via Amazon. In Europe, it is the active component of a medicine, Circadin®, consisting of a pharmaceutical prolonged release preparation, prescribed for sleep disturbances, that contains 2 mg of melatonin (10). However, no melatonin-based medicine has been approved by the US Food and Drug Administration (FDA), which has instead approved a non-selective melatonin receptor agonist, ramelteon (sold as Rozerem®) (11, 12). It is accepted that melatonin provides benefits via its putative antioxidant action or via activation of specific melatonin receptors. MT1 and MT2 receptors are the two primary melatonin membrane receptors, which belong to the superfamily of G-protein-coupled receptors (GPCRs). In both receptors, the cognate heterotrimeric protein is G_i. The biological consequence of G_i activation is inhibition of adenylate cyclase, reduction of cytosolic cAMP levels and inhibition of protein kinase A signaling pathway (13). Interestingly, other signaling pathways have also been assigned to melatonin receptor activation; one of them is just the opposite to the canonical one, i.e. G_s coupling, activation of adenylyl cyclase and increases of cytoplasmic cAMP levels (14). In addition, it has also been suggested that MT1 receptors may couple to G_q or other G proteins, and activate protein kinase C, inositol-phosphate- and calcium ion-mediated signaling (15, 16).

Quite surprisingly, a substantial number of reports show that the potency of melatonin acting on its receptors is in the picomolar range, something that it is not usual for endogenous compounds acting on GPCRs. By using high concentrations of the adenylyl cyclase activator, forskolin, many studies have shown that the potency of melatonin to its receptors is in the subnanomolar range. Furthermore, any GPCR-mediated action, if specific, must be blocked by an antagonist. Very few studies contemplate the experiment of antagonist treatment to confirm specificity and selectivity of melatonin receptor-mediated actions. In addition, atypical outputs and seemingly pleiotropic signaling [see (3, 17-20 for review] led to hypothesize the existence of a third melatonin receptor (21), which was later identified as an enzyme rather than a melatonin receptor. The enzyme, human quinone reductase 2 (22), seems to be allosterically regulated by melatonin and other endogenous compounds (e.g. N-acetylserotonin); however, its role as potential mediator of melatonin physiological effects is under discussion (23-25).

Radioligand binding assays have led to fairly low $K_D$ values of melatonin binding to its receptors. Many studies were performed with iodinated-labeled melatonin-related compounds and it is known that iodine may unspecifically bind to membranes. To our knowledge, the initial study concerning 2-[125I]iodomelatonin binding to hamster brain membranes was reported in 1986 by Duncan et al. (26). The binding potency calculated by kinetic association/dissociation data, Scatchard plot analysis and competition assays led to monophasic curves and the estimated $K_D$ value for iodomelatonin was in the low nanomolar range (3.1 to 4.9 nM). In this study the reported $K_I$ value for melatonin was 8 nM, whereas in a subsequent study using a similar preparation the reported value was 10.8 ± 2.1 nM (27). The same authors in further studies reported that the $K_D$ value of a 2-[125I]iodomelatonin binding site in the hypothalamus was 43 ± 5 pM, postulating that the hamster brain tissue shows nanomolar and picomolar affinities corresponded to, “ML-2” and “ML-1” sites, respectively (28).
A more recent study reported $K_D$ values of 332 pM and 289 pM for melatonin binding to preparations of cells expressing MT$_1$ and MT$_2$ receptors, respectively (29). In Chinese hamster ovary CHO cells expressing either MT$_1$ or MT$_2$ receptors, the significant inhibitory effects of 1 nM melatonin on 100 µM forskolin-induced cAMP cytosolic levels were observed while, surprisingly, the EC$_{50}$ values in functional studies to assess phosphoinositide signal transduction cascade were in the micromolar range. Also unusual is the high concentration (1 M) of the MT$_2$ receptor specific antagonist, cis-4-phenyl-2-propionamidotetralin (4-P-PDOT), used to block MT$_2$ receptor mediated action, while the study did not include any MT$_1$ receptor specific antagonist (29). All of these data are very intriguing from a pharmacological point of view.

It has been reported that rabbit gastrointestinal smooth muscle only expresses MT$_1$ receptor that couple to $G_q$ but not to $G_i$. For example, by use of $[^{35}S]$ GTPgammaS labeling prior to immunoprecipitation of $a$ subunits of G proteins. Ahmed et al. (30) observed that a very high concentration of melatonin (1 µM) induces an increase in the radioactivity associated to $a_q$ while the radioactivity associated to $a_{i1}$, $a_{i2}$ and $a_{i3}$ (also to $a_s$) was not significantly altered. Although melatonin promotes phosphoinositide turnover in a dose-dependent fashion with an EC$_{50}$ of 4 ± 1 nM, other functional responses (cytosolic calcium mobilization or IP hydrolysis in the presence of minigenes) require 1 µM concentration of melatonin (30). In summary, these data indicated that melatonin receptors may not couple to $G_i$ proteins and that high concentrations of melatonin are required to afford receptor functionality ($K_D$ values in the picomolar range but EC$_{50}$ values for PI hydrolysis in the low nanomolar range). Melatonin at the concentration of 1 µM decreases muscle contraction while the effect is reversed by a MT$_1$ receptor antagonist, luzindole, at a concentration of only 100 nM. If the potency of melatonin is in the nanomolar range (<10 nM according to dose-response curve illustrated in Fig. 5 of reference (30), it is difficult to believe that 100 nM luzindole will significantly inhibit the effect of melatonin at a concentration of 1 µM. In brief the MT$_1$ receptor is expressed in the muscle cells and melatonin acts via $G_q$ and not via $G_i$; however, the involvement of the receptors in the $G_q$-mediated effects is dubious as the conditions of the assays are not standard from a pharmacological point of view. In this regard, activation of melatonin receptors in a heterologous expression system does not lead to immediate Ca$^{2+}$ mobilization as it occurs in the case of other GPCRs that are coupled to $G_q$ (31).

Pre-registering is a recently developed instrument aimed at improving the reliability of results from experimental research. Pre-registered studies were first used for clinical trial implementation, but now this option is open, and convenient, for any type of scientific research. It consists of uploading detailed information of the hypothesis and the experimental designs in a database before starting the experiments. Individuals who are interested can have free access to such information. When, based on the experimental approaches, the results are obtained, they are mainly interpreted in terms of confirming or rejecting the initial hypotheses. These experimental approaches should match as much as possible to those that were a priori registered. One of the main resources is provided within the Open Science Framework (OSF), where pre-registered studies are deposited in https://osf.io. As it is stated by Foster and Deardoff (32): “Registration is a major feature of the OSF and its efforts to preserve, provide access to, and promote transparency in research. Any OSF project can be registered, which means that a time-stamped version of the project is created that cannot be edited or deleted and is intended to act as a preserved version of a project”.

As it has been already demonstrated that melatonin receptors do not couple to $G_q$ in the HEK-293T cell heterologous expression system (31), this pre-registered study (available at (33), by using the HEK-293T cell expression system, will evaluate whether i) MT$_1$ or MT$_2$ receptors can couple to $G_s$ and/or $G_i$ proteins, ii) $G_s/G_i$-coupled melatonin receptors are
sensitive to subnanomolar concentrations of melatonin and iii) melatonin potency is similar to that previously reported by using other methods to measure cAMP levels.

2. MATERIALS AND METHODS

2.1. Chemicals.

N-Acetyl-5-methoxytryptamine (melatonin), N-acetyl-2-benzyltryptamine (luzindole: non-selective MTR antagonist), cis-4-phenyl-2-propionamidotetralin (4-P-PDOT, a selective MT2R antagonist) and forskolin were purchased from Tocris Bioscience (Bristol, UK). N-[2-(2-methoxy-6H-isoindolo[2,1-a]indol-11-yl)ethyl]butanamide (IIK7, a selective MT2 receptor agonist) was purchased from Sigma-Aldrich (St. Louis, MO, USA).

2.2. Cell Culture and Transient Transfection.

A heterologous system consisting of human HEK-293T cells was used in this study. These immortalized cells come from Human Embryonic Kidney (34) and are used in many laboratories for heterologous expression of proteins. Previous heterologous expression systems were not of human origin and, accordingly, the development of HEK-293T cells was a of paramount relevance for biomolecular research; they are currently used in biochemistry, pharmacology, electrophysiology and biotechnology approaches aimed at advancing knowledge into protein structure/function relationships (35-37). Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 2 mM L-glutamine, 100 U/ml penicillin/streptomycin, and 5% (v/v) heat inactivated fetal bovine serum (FBS) (Invitrogen, Paisley, Scotland, United Kingdom). Cells were maintained in a humid atmosphere of 5% CO2 at 37°C. Cells were transiently transfected with the polyethyleneimine (PEI, Sigma, St. Louis, MO, United States) method (38-40). Briefly, cells were incubated (4h) in a serum-starved medium with the corresponding cDNA and with PEI (5.47 mM in nitrogen residues) and 150 mM NaCl. After 4 hours, the medium was replaced by a fresh complete culture medium. The cDNAs used were obtained from the cDNA resource Center (Ref. #MTNR1A0000 for the MT1 receptor and #MTNR1B0000 for the MT2 receptor). Transfection efficiency (>60% of cells expressing each of the receptors) was checked using specific antibodies and immunocytochemical staining.

2.3. cAMP determination.

Two hours before initiating the experiment, HEK-293T cell-culture medium was replaced by serum-starved DMEM medium. Then, cells were detached and suspended in growing medium containing 50 mM zardaverine. Cells were plated in 384-well microplates (2,500 cells/well), pretreated (15 min) with the corresponding antagonists or vehicle and stimulated with agonists and 0.5 µM forskolin or vehicle (15 min). Readings were performed after 1 h incubation at 25 °C. Homogeneous time-resolved fluorescence energy transfer (HTRF) measures were performed using the Lance Ultra cAMP kit (PerkinElmer, Waltham, MA, USA). Fluorescence at 665 nm was analyzed on a PHERAstar Flagship microplate reader equipped with an HTRF optical module (BMG Lab technologies, Offenburg, Germany).
2.3. Statistical Analysis

Data were analyzed using Prism 7 (GraphPad Software, Inc., San Diego, CA, United States). The data in graphs are the mean ± SEM. Significance was analyzed by one-way ANOVA, followed by Bonferroni’s multiple comparison post hoc test. Significant differences were considered when \( p < 0.05 \).

3. RESULTS

Although \( G_i \) is the cognate heterotrimeric protein coupled to melatonin receptors, as classified by the International Union of Pharmacology and British Society of Pharmacology (13) (https://www.guidetopharmacology.org/), there have been reports on coupling to \( G_s \), so we first tested whether activation of melatonin receptors increases cAMP production. Results in Figure 1A and 1C show that neither melatonin treatment on MT1-expressing HEK-293T cells or on MT2-expressing HEK-293T cells led to any significant increase in cytosolic cAMP levels. Therefore, in a heterologous expression system, the human versions of MT1 and MT2 receptors are likely not \( G_s \)-coupled. In contrast, in the same experimental system, melatonin treatment significantly decreased the cAMP levels which previously increased upon 0.5 \( \mu \text{M} \) forskolin treatment.

Forskolin treatment increased cytosolic cAMP levels in both cell lines (also in untransfected cells) and this increase was reduced by cotreatment with melatonin at the concentration of 100 nM in both MT1-expressing and MT2-expressing cells. In addition, it is evidenced that melatonin membrane receptors are coupled to \( G_i \) in a specific manner, as the cAMP-inhibitory effect is completely blocked by the non-selective antagonist, luzindole (N-acetyl-2-benzyltryptamine, 1 \( \mu \text{M} \)), in MT1-expressing cells and by the MT2 receptor selective antagonist, 4-P-PDOT (0.5 \( \mu \text{M} \)), in MT2-expressing cells. These antagonists in the absence of melatonin did not significantly affect the forskolin effect on cAMP production (Figure 1B and D). The results confirmed that both MT1 and MT2 were specifically coupled to \( G_i \) (Figure 1B and D).

**Fig. 1. Assessment of \( G_s \) and \( G_i \) coupling.**

HEK-293T cells expressing MT1 receptor (A, B) or MT2 receptor (C, D) treated with vehicle or with either 1 or 100 nM melatonin. \( G_s \) coupling (A, C) was assessed by measuring the increase of cytosolic cAMP levels whereas \( G_i \) coupling (B, D) was assessed by simultaneous...
treatment with 0.5 µM forskolin. Cytosolic cAMP levels were determined by TR-FRET as described in Methods. Specificity was assessed by preincubating cells with antagonists (for 15 min): the melatonin receptor nonselective antagonist, luzindole, in MT1-expressing cells (B) and the MT2 receptor selective antagonist, 4-P-PDOT, in MT2-expressing cells (D). Values are the mean ± SEM of 6 independent experiments performed in triplicates. One-way ANOVA followed by Bonferroni’s multiple comparison post hoc test were used for statistical analysis (*p < 0.05, ***p < 0.001 versus forskolin treatment).

To further assess receptor functionality, dose response assays were performed. At subnanomolar levels, no significant inhibitory effect of melatonin (MT1 expressing cells) or of melatonin or IIK7 (MT2 expressing cells) was detected in forskolin-induced cAMP determination experiments (Figure 2A and B). The calculated IC50 value of melatonin on the MT1 receptor was 58.0 nM (pIC50=7.24, SD 0.35) and IC50 values of melatonin and IIK7 on the MT2 receptor were 3.9 nM (pIC50=8.4, SD 0.22) and 7.3 nM (pIC50=8.1, SD 0.22), respectively (Figure 3A and B).

Fig. 2. Effects of melatonin and IIK7 on forskolin-induced cAMP production in MT1 or MT2 expressing cells.

HEK-293T cells expressing MT1 receptor (A) or MT2 receptor (B) were treated with 0.5 µM forskolin and melatonin and/or IIK7 (selective MT2 agonist) at the indicated concentrations. In parallel, assays with cells pretreated (15 min) with antagonists: luzindole or 4-P-PDOT, were also performed. Cytosolic cAMP levels were determined by TR-FRET as described in Methods. Values are the mean ± SEM of 6 independent experiments performed in triplicates. No statistically significant differences were observed in any of the treatments (versus the forskolin treatment).

The antagonistic assays were carried out in MT2-expressing cells treated with melatonin or with the selective MT2 agonist IIK7 (100 nM) plus the selective MT2 antagonist, 4-P-PDOT, and, in MT1-expressing cells with melatonin plus luzindole. The results showed that the effect of 100 nM melatonin was blocked by 1 µM luzindole (Figure 3C) and both the effects of 100 nM melatonin or 100 nM IIK7 were completely blocked by 0.5 µM 4-P-PDOT (Figure 3D). Taken together, the data suggest that i) the effect was specifically due to action on MT1 or MT2, ii) the potency of melatonin was lower on MT1 receptor than on MT2 receptor and ii) the
potency of the endogenous (melatonin) and the synthetic (IIK7) agonists is similar (in the low nM range) for MT₂ receptor.

Fig. 3. Dose-response curves and selectivity of antagonists of MT₁ and of MT₂.
Melatonin and/or IIK7 dose-response curves in HEK-293T cells expressing MT₁ receptor (A) or in cells expressing MT₂ receptor (B). The conditions of the assay to measure effects on forskolin-induced cAMP levels were similar to those described in figure 1. Specificity of the effect was shown using luzindole in MT₁-expressing cells (C) and 4-P-PDOT in MT₂-expressing cells (D). Panels C-D: Values are the mean ± SEM. of 6 independent experiments performed in triplicates. One-way ANOVA followed by Bonferroni’s multiple comparison post hoc test were used for statistical analysis (*p < 0.05, ***p < 0.001 versus forskolin treatment).

4. DISCUSSION

The results here presented corroborate the hypothesis of the pre-registered study, i.e. the potency of melatonin does not lie in the pM but in the low nM range for MT₂ and in the high nM range for MT₁ receptor. This seems different from previous concepts on the melatonin receptor potency. Anyway, the data will provide a new look and new vistas as to the melatonin’s biology and on the role of melatonin receptors in melatonin physiological functions (41).

Melatonin receptors when expressed in HEK-293T cells specifically couple to Gᵢ and not to Gₛ (observed in the present study) or to Gᵦ₈ (31). This fits well with the canonical pathway defined by the International Union of Pharmacology and British Society of Pharmacology (https://www.guidetopharmacology.org/). The possibility of melatonin receptors coupling to Gᵢ or Gᵦ₈ (even to G₁₅) proteins reported in CHO cells, in cell lines or in intact tissues (16, 30, 42-44) was not contemplated in this pre-registered study. However, data from our own laboratory have shown that Gᵢ or G₉ coupling may occur by formation of complexes involving melatonin receptors and other GPCRs [31]. It seems that the real potency of melatonin on the MT₁ is lower than that previously described but such potency in terms of EC₅₀ or IC₅₀ values for proximal signaling is similar to that of other endogenous compounds acting on the
populated GPCR superfamily. In addition, the data related to MT₂ receptor were consistent with the data reported in hamster brain [26–28].

There are two main inconsistencies brought about by this pre-registered study. One is related to MT₂ receptor as our results are consistent with those of Duncan et al., who reported 8-10.8 nM $K_D$ values for melatonin, but not with other laboratories reporting picomolar $K_D$ values. Another is related to MT₁ receptor. Almost all laboratories have claimed the potency of melatonin on it is in the range of pM for both $K_D$ of radioligand binding and IC₅₀ of Gₛ-mediated effects. In a study using the same cells employed here, HEK-293 cells, forskolin-induced cAMP determinations in cells expressing MT₁ or MT₂ receptor led to IC₅₀ values for melatonin being 7.7 and 117 pM, respectively (45). Thus, the differences between this report and ours do not seem due to the melatonin receptor expression system. However, in our study, the receptor specificities are investigated and this is not the case in the report by Conway et al. (45). In sharp contrast, the effect that we have demonstrated was, on either melatonin receptor, specifically blocked by selective receptor antagonists (Figure 3C and D).

The sequences of the plasmids used in our study are the canonical ones: GeneBank accession number NM005958 for MT₁ and AY521019 for MT₂ receptor, which are the same as the ones used by Conway et al. (45). Thus, the differences between their study and ours may come from the concentration of forskolin, the method of cAMP level determination, which is now more reliable than before, and also from the approach for data acquisition and analysis.

Two logical questions raise from the high potency and the $K_D$ values in the pM range found using either MT₁ or MT₂ in previously published articles: i) the specificity is (often) not confirmed by antagonism and ii) if the potency and $K_D$ are picomolar why melatonin is used at micromolar concentrations when assessing its physiological effects?

In summary, in this pre-registered study two important issues on melatonin research have been confirmed, that are, 1. both MT₁ and MT₂ receptors are directly coupled with Gₛ but not with Gₛ and G_q (may be associated with them depending on the context, as mentioned in the text); 2. the melatonin potency in both MT₁ and MT₂ receptors is significantly lower (nM) than that previously reported (pM). We believe that these new data, especially on the potency of melatonin on its receptors will provide a new perspective in melatonin research. It is important to consider that the amount of melatonin needed to achieve its physiological or therapeutic effects may be much higher than that of previously thought.

ACKNOWLEDGEMENTS

In memoriam of Jesús (Suso Pintor) an outstanding scientist and yet a good person.

AUTHOR CONTRIBUTIONS

RF and late JP designed the study. RF, RRS, IRR, HAA and GN pre-registered the study. RRS with the help of IU in terms of cell culturing and reagent preparation performed the experiments designed by GN, HAA and RF. RF, RRS, IRR, HAA and GN analyzed the results. RF supervised the work in relation to adherence to pre-registration terms. RRS and GN wrote the Methods section and RF prepared a first version of the manuscript that was further edited by RRS, IRR, HAA and GN. All authors have read and approved the submitted version of the manuscript.
CONFLICT OF INTERESTS

Authors declare no conflict of interest.

REFERENCES

1. Lerner AB, Case JD (1959) Pigment cell regulatory factors. J. Invest. Dermatol. 32: 211–221.
2. Lerner AB, Case JD, Takahashi (1960) Isolation of melatonin and 5-methoxyindole-3-acetic acid from bovine pineal glands. J. Biol. Chem. 235: 1992–1997.
3. Emet, M, Ozcan, H, Ozel L, Yayla M, Halici Z, Hacimuftuoglu A (2016) A review of melatonin, its receptors and drugs. Euras. J. Med. 48: 135–141.
4. Crooke A, Huete-Toral F, Colligris B, Pintor J (2017) The role and therapeutic potential of melatonin in age-related ocular diseases. J. Pineal Res. 63: e12430.
5. Cecon E, Oishi A, Jockers R (2017) Melatonin receptors: molecular pharmacology and signalling in the context of system bias. Br. J. Pharmacol. 175: 3263–3280.
6. Carracedo G, Carpena C, Concepción P, Díaz V, García-García M, Jemni N, et al. (2017) Presence of melatonin in human tears. J. Optometry 10: 3–4.
7. Zaccara G, Schmidt D (2018) Antiepileptic drugs in clinical development: Differentiate or Die? Curr. Pharm. Des. 23: 5593–5605.
8. Wade AG, Ford I, Crawford G, McConnachie A, Nir T, Laudon M, et al. (2010) Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 8: 51.
9. Gringras P, Nir T, Breddy J, Frydman-Marom A, Findling RL (2017) Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J. Am. Acad. Child. Adolesc. Psychiat. 56: 948–957.
10. Alston M, Cain SW, Rajaratnam SMW (2019) Advances of melatonin-based therapies in the treatment of disturbed sleep and mood. Handbook Exp. Pharmacol. 253: 305-319.
11. Low TL, Choo FN, Tan SM (2020) The efficacy of melatonin and melatonin agonists in insomnia – An umbrella review. J. Psychiatr. Res. 121: 10–23.
12. Atkin T, Comai S, Gobbi G (2018) Drugs for insomnia beyond benzodiazepines: Pharmacology, clinical applications, and discovery. Pharmacol. Rev. 70: 197–245.
13. Alexander SP, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA et al. (2017) The concise guide to Pharmacology 2017/18: G protein-coupled receptors. Br. J. Pharmacol. 174: S17–S129.
14. Huete-Toral F, Crooke A, Martínez-Águila A, Pintor J, Martinez-Aguila A, Pintor J. et al. (2015) Melatonin receptors trigger cAMP production and inhibit chloride movements in nonpigmented ciliary epithelial cells. J. Pharmacol. Exp. Ther. 352: 119–128.
15. Vanecek J. (1998) Cellular mechanisms of melatonin action. Physiol. Rev. 78: 687–721.
16. Brydon L, Roka F, Petit L, De Coppet P, Tissot M, Barrett P. et al. (1999) Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3), and G(q/11) proteins. Mol. Endocrinol. 13: 2025–2038.
17. Dubocovich ML, (1995) Melatonin receptors: Are there multiple subtypes? Trends Pharmacol. Sci. 16: 50–56.
18. Blask DE, Hill SM, Dauchy RT, Xiang S, Yuan L, Duplessis T, et al. (2011) Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night. J. Pineal Res. 51: 259–269.
19. Sugden D, Davidson K, Hough KA, Teh MT (2004) Melatonin, melatonin receptors and
molecular biology, and electrophysiology. Cells Tissues Organs. S. Karger AG. p. 1–8.

Melatonin Res. 2019, Vol 2 (4) 121-131; doi: 10.32794/mr11250044 130
38. Hinz S, Navarro G, Borroto-Escuela D, Seibt BF, Ammon C, de Filippo E, et al. (2018) Adenosine A2A receptor ligand recognition and signaling is blocked by A2B receptors. *Oncotarget* 9: 13593–13611.

39. Navarro G, Borroto-Escuela D, Angelats E, Etayo I, Reyes-Resina I, Pulido-Salgado M, et al. (2018) Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer’s disease and levodopa-induced dyskinesia. *Brain, Behav. Immun.* 67: 139–151.

40. Reyes-Resina I, Navarro G, Aguinaga D, Canela EI, Schoeder CT, Zaluski M, et al. (2018) Molecular and functional interaction between GPR18 and cannabinoid CB2 protein-coupled receptors. Relevance in neurodegenerative diseases. *Biochem. Pharmacol.* 157: 169-179.

41. Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML (2016) MT 1 and MT 2 Melatonin Receptors: A Therapeutic Perspective . *Ann. Rev. Pharmacol. Toxicol.* 56: 361–383.

42. Shiu SY, Pang B, Tam CW, Yao KM (2010) Signal transduction of receptor-mediated antiproliferative action of melatonin on human prostate epithelial cells involves dual activation of Galpha(s) and Galpha(q) proteins. *J. Pineal Res.* 49: 301-311.

43. Lai FP, Mody SM, Yung LY, Kam JY, Pang CS, Pang SF, Wong YH (2002) Molecular determinants for the differential coupling of Galpha(16) to the melatonin MT1, MT2 and Xenopus Mel1c receptors. *J. Neurochem.* 80: 736-745.

44. Mody SM, Ho MK, Joshi SA, Wong YH, (2000) Incorporation of Galpha(z)-specific sequence at the carboxyl terminus increases the promiscuity of galpha(16) toward G(i)-coupled receptors. *Mol. Pharmacol.* 57: 13-23.

45. Conway S, Drew JE, Canning SJ, Barrett P, Jockers R, Strosberg AD, et al. (1997) Identification of Mel1a melatonin receptors in the human embryonic kidney cell line HEK293: evidence of G protein-coupled melatonin receptors which do not mediate the inhibition of stimulated cyclic AMP levels. *FEBS Lett.* 407: 121–126.

---

This work is licensed under a [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/).

**Please cite this paper as:**

**Rivas-Santisteban, R., Reyes-Resina, I., Raich, I., Pintor, J., Alkozi, H., Navarro, G. and Franco, R. 2019. Specificity and nanomolar potency of melatonin on G-protein coupled melatonin MT1 and MT2 receptors expressed in HEK-293T human embryo kidney cells. Melatonin Research. 2, 4 (Dec. 2019), 121-131.**

**DOI:** [https://doi.org/https://doi.org/10.32794/mr11250044](https://doi.org/https://doi.org/10.32794/mr11250044)